stockrow
Friday 6 November 2026
Export IMVT’s income statement to Excel — free account
Immunovant, Inc.
IMVT Healthcare Biotechnology
- EPS
- −5.63%
- Free cash flow
- −5.96%
Quarter to June 2026, against a year earlier
30.53
2.14
+7.54%
Follow IMVT
Alert me
Immunovant, Inc. (IMVT) EPS (diluted)
Immunovant, Inc.'s EPS (diluted) for fiscal 2026 was −$2.77, compared with −$2.73 in fiscal 2025. Over the twelve months to 30 June 2026 it was −$2.82. Over the past ten years it has ranged from −$2.77 (fiscal 2026) to $0.00 (fiscal 2018) — the current reading is the lowest in ten years. EPS (diluted) has fallen for 5 consecutive fiscal years. Immunovant, Inc. ranks 368th of 580 Biotechnology companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2026 | −$2.77 | — |
| FY2025 | −$2.73 | — |
| FY2024 | −$1.88 | — |
| FY2023 | −$1.71 | — |
| FY2022 | −$1.43 | — |
| FY2021 | −$1.22 | — |
| FY2020 | −$1.54 | — |
| FY2019 | −$1.29 | — |
| FY2018 | $0.00 | — |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Jun 2026 | −$0.75 | — |
| Mar 2026 | −$0.73 | — |
| Dec 2025 | −$0.61 | — |
| Sep 2025 | −$0.73 | — |
| 26 more quarters | Free account |
Against its own ten years
Low −$2.77
High $0.00
Ten-year median
−$1.54
Current reading's percentile
11
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| LGND Ligand Pharmaceuticals Incorporated compare | $2.24 |
| PTCT PTC Therapeutics, Inc. compare | −$1.40 |
| CGON CG Oncology, Inc. compare | −$2.69 |
| BLTE Belite Bio, Inc. Sponsored ADR compare | −$2.73 |
| IMVT Immunovant, Inc. | −$2.82 |
| IONS Ionis Pharmaceuticals, Inc. compare | −$3.46 |
| KOD Kodiak Sciences Inc. compare | −$4.19 |
| MIRM Mirum Pharmaceuticals, Inc. compare | −$15.22 |
| MANE Veradermics Incorporated compare | −$45.88 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item